OncoMatch/Clinical Trials/NCT04901936
A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Is NCT04901936 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Pegcetacoplan for paroxysmal nocturnal hemoglobinuria (pnh).
Treatment: Pegcetacoplan — The purpose of this study is to evaluate the safety, effectiveness, and biological activity (how the investigational medication is processed by the body) of pegcetacoplan in 12-17 year-olds (adolescents) who have paroxysmal nocturnal hemoglobinuria (PNH).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Demographics
Lab requirements
Blood counts
platelet count >75,000/mm3 and absolute neutrophil count >1000/mm3
Have a platelet count >75,000/mm3 and an absolute neutrophil count >1000/mm3
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Children's Hospital of Atlanta · Atlanta, Georgia
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04901936 currently recruiting?
Yes, this trial is currently recruiting patients.
Is there an age limit?
Yes. Patients must be 17 years or younger and at least 12 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify